Palivizumab profilaksa RSV infekcije

Abstract

Introduction: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children.

Material and methods: Observational study, in Tuzla Canton, Bosnia and Herzegovina (B&H), reports of infants at high risk for RSV who received at least 1 dose of palivizumab during the 2008-2016 RSV seasons.

Results: Across 8 RSV seasons, from 2008/9 to 2016/17, 267 infants were enrolled (0.66% of livebirths population). Of all infants,147 (55.0%) were enrolled for prematurity only, 7 (2.6%) for bronchopulmonary dysplasia/ chronic lung disease (BPD/CLD), 115 (43.0% ) for congenital heart disease (CHD), and 5 (1.8%) for other reasons; 129 (46.3%) infants in total were born before 33 weeks. Average gestational age of preterm infants enrolled for prematurity only was 30.1±1.2 weeks; for preterm infants with BPD/CLD it was 30±1.3weeks. Overall average of palivizumab injections was 3.9±1.1. Hospitalization rate related to severe lower respiratory infections (LRI) during the period of protection by palivizumab was 3.3%. Respiratory infections which deserved medical attention were observed in 6.3% infants included in palivizumab prophylaxis.

Conclusion: RSV prophylaxis in Tuzla Canton is provided systematically and successfully, following the national guidance established in 2009. with low hospitalization rate for severe LRI in prophylaxed infants..